Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus glimepiride in MODY3
2012-000592-17Phase 2Completed
- Sponsor
- Signe H. Østoft, Diabetes Research Division
- Start
- Jul 2012
- Modality
- Peptides, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liraglutide and glimepiride in Maturity Onset Diabetes of the Young (MODY) (2 arms), sponsored by Signe H. Østoft, Diabetes Research Division. Primary endpoint: Fasting plasma glucose. Started Jul 2012; status: completed.
02
Drugs
liraglutideglimepiride
03
Conditions
Maturity Onset Diabetes of the Young (MODY)
Beyond the preview
Go deeper on 2012-000592-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000592-17.